CN105456193A - EGCC liposome preparation and preparation method thereof - Google Patents
EGCC liposome preparation and preparation method thereof Download PDFInfo
- Publication number
- CN105456193A CN105456193A CN201510934821.7A CN201510934821A CN105456193A CN 105456193 A CN105456193 A CN 105456193A CN 201510934821 A CN201510934821 A CN 201510934821A CN 105456193 A CN105456193 A CN 105456193A
- Authority
- CN
- China
- Prior art keywords
- preparation
- egcg
- liposome
- egcc
- lipoid plastid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to EGCC liposome, and relates to a preparation method of the EGCC liposome, in which liposome is prepared through an ethanol injection method. EGCC has efficient antioxidant activity and biological activity; aiming at the problem that EGCC easily has degradation and is low in in-vivo bioavailability due to the influences of the external conditions, EGCG is innovatively embedded into the liposome, so that the influences of the external conditions are alleviated, the stability of EGCG in the digestion process of the gastrointestinal tract is enhanced, and further, the effect of improving the bioavailability of EGCG is improved. The prepared EGCC liposome is in the form of regular spherical bimolecular vesicae, and the embedding rate achieves 70%; the grain diameter of the EGCC liposome is 70-200 nm, and is uniform in distribution; and the EGCC liposome is stable within three months. The ethanol injection method is adopted in the preparation technology, the steps are simple, compared with the other preparation methods, the mixing of poisonous organic reagents is avoided, the safety is high, and the preparation method is suitable for industrial production. A wall material adopted by the liposome is a nonionic surfactant, is harmless to the human body, and is easily biodegradable; compared with phospholipids, the nonionic surfactant is difficult to oxidize and low in cost, and is good in stability, and easy in biological uptake.
Description
Technical field
The present invention relates to food, cosmetics, nutritional preparation and preparation method technical field, the preparation method of a kind of lipoid plastid and preparation thereof is provided further.
Background technology
Epigallocatechin gallate (EGCG) (EGCG) is the effective ingredient that in green tea catechins, content is the highest.EGCG, as a kind of good chemopreventive agent, has been found to have multiple biological activity, comprises high anti-oxidation activity, antitumor, improves cardiovascular disease, defying age, the effect such as weight reducing and the skin injury that causes of protection ionizing radiation.But, EGCG self extremely unstable, oxidizable in the solution, lose hydrogen atom, generate Semiquinone Radicals, final formation quinones oxidation product; And be subject to the impact of environmental factors, the pH value of the concentration of temperature, EGCG, antioxidant, oxygen content and partial neutral or alkalescence all can have a strong impact on the stability of EGCG.On the other hand, EGCG is difficult to by intestinal absorption; Easily be oxidized by dissolved oxygen in alkaline intestinal juice environment, the bioavailability that result also in EGCG is low, is difficult to the effect playing its antioxidant activity in human body.The low bioavailability of EGCG limits its application & development at food, medicine, cosmetic industry.Therefore, design a kind of nano-carrier and be applied to encapsulating EGCG to improve its physicochemical stability in storage, and absorption in human body intestinal canal thus reach improves bioavailability and is one and has potentiality and feasible method.
Vesicle, as a kind of medicament transport carrier, because of the amphipathic characteristic of its constitute, has the significant advantage that can embed numerous chemical combination materials.Liposome is the spherical folliculus of ultra micro formed by phospholipid bilayer tunic, phospholipid molecule has hydrophilic and lipophilic group, they are well-regulated arrangement in aqueous phase, form bilayer ball shape structure, water soluble ingredient can be wrapped in aqueous phase, and liposoluble constituent can be positioned between bilayer lipid membranes.Therefore liposome can embed lipophilic molecule and water soluble molecules simultaneously.But the structure of liposome mainly contains phospholipid composition, and phospholipid key is easily oxidized when usually preserving, cause embedding thing seepage; The price valency of phospholipid is high simultaneously, is unfavorable for the embedding of low cost material.And the appearance of lipoid plastid overcomes these problems, lipoid plastid refers to non-ionic surface active agent replacement phospholipid, and adds the vesicle helping membrane formation to be similar to liposome structure.Compared with liposome, lipoid plastid not only itself is stablized, and can increase the stability of packaging medicine; Its film material non-ionic surface active agent does not need special process and low temperature storage; Because having numerous non-ionic surface active agent kind for selecting, therefore lipoid plastid has architectural characteristic (composition, mobility and size) multiformity, can design as requested, as allowed hydrophilic group contact surface, hydrophilic group can be mixed in bilayer and changing behavior in its body; Lipoid plastid also can be processed to delay drug release further, as being emulsified in nonaqueous phase by the aqueous dispersion of lipoid plastid, with regulating drug rate of release.Simultaneously due to lipoid plastid particle diameter less (<150nm), be not easy by macrophage phagocytic, circulation time in vivo can be extended, there is excellent tissue permeability, especially can assemble having leaky blood vessel tissue (tumor, inflammation district or infarcted region etc.); Lipoid plastid is not easily by renal excretion, and the liposome that particle diameter is large also can concentrate at liver, spleen, and has passive target effect; Nano level lipoid plastid also can avoid intestinal to the removing of EGCG, transforms, degraded, strengthen the interaction with intestinal tract surface, thus enhancing absorbs.
Film dispersion method and reverse evaporation are the common methods preparing lipoid plastid, injection method uses less in document and application, in the majority with ether injection, effect preparation method of the present invention is alcohol injection, ether is replaced with ethanol, the method not only can be avoided using toxic solvent (as chloroform, methanol), expensive detergent (cholate) and other too controversial raw material, and the particle diameter of lipoid plastid can be controlled, the number of plies and stability, simple and easy to do, favorable reproducibility, finally ultrafiltration can be adopted as required, dialysis, the mode such as reverse osmosis or reduction vaporization removes ethanol, to reach the particular requirement of preparation.
Embedding EGCG lipoid plastid prepared by the present invention and preparation thereof, can reduce the loss of EGCG in storage and digestion process; Strengthen small intestinal to the absorption of EGCG, improve its bioavailability; In addition the wall material selected by lipoid plastid is non-ionic surface active agent, harmless, with low cost, thus can create larger economic benefit; Select alcohol injection to be preparation method, the lipoid plastid vesicle of preparation uniform particle diameter that can be simple and quick, and storage-stable is good, is applicable to large-scale production.
Summary of the invention
The technical problem to be solved in the present invention is open a kind of lipoid plastid preparation embedding EGCG, there is provided a kind of cost comparatively cheap, there is good stability, nanoscale is beneficial to intestinal absorption, strengthen EGCG storage and digestion stability and the lipoid plastid suspension of intestinal absorption characteristic, provide its preparation method simultaneously, thus solve an above-mentioned difficult problem for its suitability for industrialized production.
Technical scheme of the present invention: a kind of preparation method of EGCG lipoid plastid preparation, is characterized in that its compositing range is: embedding thing 2 ~ 5%, carrier 98 ~ 95%;
Described embedding thing is anti-oxidation active substance, is epigallocatechin gallate (EGCG) EGCG here.
Described carrier is non-ionic surface active agent, membrane structure regulator, stabilizing agent, wherein non-ionic surface active agent 48% ~ 65%, membrane structure regulator 30% ~ 50%, stabilizing agent 0 ~ 7%.
Described non-ionic surface active agent is one or more in Span60, Span40, Tween60, Tween61, Tween20, Tween40, Brij30, and regulates transition temperature range to be 45 DEG C ~ 65 DEG C.
In described lipoid plastid, the HLB value of non-ionic surface active agent is 3 ~ 12.
Described membrane structure regulator is one or more in cholesterol, dodecanol, Dihexadecylphosphate, and addition is 2 ~ 50%.
In described lipoid plastid, also can dose two Cetyl Phosphate used as stabilizers, and be 1:(0 ~ 1.5 by the quality proportioning of medicine carrying thing).
The preparation method of described EGCG lipoid plastid preparation is alcohol injection, comprises the following steps:
A) get non-ionic surface active agent, cholesterol, EGCG according to the above ratio, add ethanol and make it dissolve;
B) above-mentioned organic solution is slowly injected in the deionized water of stirring in water bath at 30 ~ 80 DEG C, stirs 0.5 ~ 2h, form lipoid plastid suspension;
C) reduce pressure the above-mentioned lipoid plastid suspension of rotary evaporation, removing organic solvent wherein.
In step (c), rotating evaporation temperature of the present invention is 30 ~ 60 DEG C, and rotating speed is 90 ~ 100r/min, and pressure is 0.5 ~ 1MPa.
Prepare lipoid plastid as stated above.This invention lipoid plastid has the ability strengthening EGCG storage and digestion stability and intestinal absorption characteristic.Non-ionic surface active agent is as main wall material simultaneously, harmless, with low cost.Lipoid plastid of the present invention has good stability, and technique is simple, is applicable to large industrial feature.
Beneficial effect of the present invention:
(1) replace expensive phospholipid to prepare lipoid plastid preparation by harmless non-ionic surface active agent, save production cost; Lipoid plastid can protect EGCG in storage simultaneously, reduces the loss of EGCG, the color change that reduction EGCG causes because of its unstability and flavor variations (bitter taste).
(2) lipoid plastid can strengthen the stability of EGCG in digestion process, and its nano level structure also contributes to EGCG by intestinal absorption, strengthens the bioavailability of EGCG.
Accompanying drawing explanation
The particle size distribution of Fig. 1 EGCG lipoid plastid and TEM figure.
Storage stability in Fig. 2 EGGC lipoid plastid 90 days.
The digestion release conditions of Fig. 3 EGCG lipoid plastid in intestinal.
Detailed description of the invention
Embodiment 1
Get Span60:50mg, cholesterol: 50mg, EGCG5mg, be dissolved in 60 DEG C altogether, in 2mL ethanol, solution be at the uniform velocity expelled to 20mL, in the PBS buffer of 60 DEG C, stir aquation 30min with the speed of 90 ~ 100r/min at 60 DEG C, in 50 DEG C, rotate evaporating ethanol under 0.1MPa, i.e. obtained lipoid plastid suspension.
Embodiment 2
Get Span40:50mg, cholesterol: 50mg, EGCG5mg, be dissolved in 60 DEG C altogether, in 2mL ethanol, solution be at the uniform velocity expelled to 20mL, in the PBS buffer of 60 DEG C, stir aquation 30min with the speed of 90 ~ 100r/min at 60 DEG C, in 50 DEG C, rotate evaporating ethanol under 0.1MPa, i.e. obtained lipoid plastid suspension.
Embodiment 3
Get Tween80:50mg, cholesterol: 50mg, EGCG5mg, be dissolved in 60 DEG C altogether, in 2mL ethanol, solution be at the uniform velocity expelled to 20mL, in the PBS buffer of 60 DEG C, stir aquation 30min with the speed of 90 ~ 100r/min at 60 DEG C, in 50 DEG C, rotate evaporating ethanol under 0.1MPa, i.e. obtained lipoid plastid suspension.
Embodiment 4
Get Tween60:50mg, cholesterol: 50mg, EGCG5mg, be dissolved in 60 DEG C altogether, in 2mL ethanol, solution be at the uniform velocity expelled to 20mL, in the PBS buffer of 60 DEG C, stir aquation 30min with the speed of 90 ~ 100r/min at 60 DEG C, in 50 DEG C, rotate evaporating ethanol under 0.1MPa, i.e. obtained lipoid plastid suspension.
Embodiment 5
Get Tween20:50mg, cholesterol: 50mg, EGCG5mg, be dissolved in 60 DEG C altogether, in 2mL ethanol, solution be at the uniform velocity expelled to 20mL, in the PBS buffer of 60 DEG C, stir aquation 30min with the speed of 90 ~ 100r/min at 60 DEG C, in 50 DEG C, rotate evaporating ethanol under 0.1MPa, i.e. obtained lipoid plastid suspension.
Embodiment 1 to embodiment 5, by measuring envelop rate and the change of size of EGCG lipoid plastid, obtaining the lipoid plastid uniform particle diameter prepared by alcohol injection, having good stability, and can keep stable in 3 months; And compared to Span series, the lipoid plastid particle diameter of Tween series is less, and envelop rate is higher.Made EGCG lipoid plastid keeps stable in gastric juice, slow releasing in intestinal.
In sum, less with the lipoid plastid particle diameter prepared by alcohol injection, even particle size distribution, stronger compared to other preparation methoies (thin film-dispersion method, reverse evaporation) storage-stable, and higher envelop rate can be obtained, be a kind of harmless, with low cost, prepare simple and quick, and storage-stable is good, be applicable to the preparation method of large-scale production.
Claims (5)
1. a lipoid plastid preparation, is characterized in that: adopt nonionic surfactant as lipoid plastid film material, obtains by adding membrane structure regulator in preparation process;
Selected non-ionic surface active agent, is characterized in that: one or more in Span60, Span40, Tween60, Tween61, Tween20, Tween40, Brij30, and regulates transition temperature range to be 45 DEG C ~ 65 DEG C, and HLB value is 3 ~ 12;
Described membrane structure regulator, is characterized in that: one or more in cholesterol, dodecanol, Dihexadecylphosphate, and addition is 2 ~ 50%.
2. lipoid plastid preparation as claimed in claim 1, it is characterized in that: described lipoid plastid preparation also comprises core, described core is epigallocatechin gallate (EGCG) (EGCG), and wherein the weight ratio of core and wall material (non-ionic surface active agent and membrane structure regulator) is 1:50 ~ 1:10.
3. the preparation method of lipoid plastid as claimed in claim 1 is alcohol injection, comprises the following steps:
By non-surface ionic active agent, membrane structure regulator and EGCG congruent melting in ethanol, solution is at the uniform velocity expelled in deionized water or PBS buffer, aquation is stirred with the speed of 90 ~ 100r/min, with the alcohol solvent that rotary evaporation devices removing is remaining, i.e. obtained lipoid plastid suspension.
4. the preparation method as described in right 3, is characterized in that: described alcohol solvent melting temperature is 30 ~ 80 DEG C; Aqueous medium preheat temperature and hydration temperature are 30 ~ 60 DEG C; Hydration time is 0.5 ~ 2h; Rotating evaporation temperature is 30 ~ 60 DEG C, and the pressure of rotary evaporation is 0.5 ~ 1MPa.
5. the application of the lipoid plastid preparation as described in as arbitrary in claim 1 ~ 2, is characterized in that: can make an addition in beverage, mastic, gel, keeps stable 4 DEG C ~ 25 DEG C time, and in human gastric juice, is keeping stable, slow releasing EGCG in intestinal juice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510934821.7A CN105456193A (en) | 2015-12-15 | 2015-12-15 | EGCC liposome preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510934821.7A CN105456193A (en) | 2015-12-15 | 2015-12-15 | EGCC liposome preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456193A true CN105456193A (en) | 2016-04-06 |
Family
ID=55594662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510934821.7A Pending CN105456193A (en) | 2015-12-15 | 2015-12-15 | EGCC liposome preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456193A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919824A (en) * | 2016-07-07 | 2016-09-07 | 北京浩奇科技有限责任公司 | EGCG-containing oily cosmetic, as well as preparation method and application thereof |
| CN107320716A (en) * | 2017-06-27 | 2017-11-07 | 珠海亿胜生物制药有限公司 | Basic fibroblast growth factor vesica and preparation method thereof |
| CN109464298A (en) * | 2018-11-20 | 2019-03-15 | 江南大学 | A kind of preparation method and EGCG lipoid plastid gel of EGCG lipoid plastid gel |
| CN110999988A (en) * | 2019-12-20 | 2020-04-14 | 茗汲(浙江)生物科技有限公司 | Preparation method of white tea and tea seed oil microcapsules |
| CN116602959A (en) * | 2023-05-24 | 2023-08-18 | 广州中妆美业化妆品有限公司 | Composition liposome containing tea active ingredient and having anti-inflammatory and analgesic effects and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612124A (en) * | 2009-07-15 | 2009-12-30 | 吉林大学 | The preparation method of a kind of lipoid plastid and preparation thereof |
| CN102670508A (en) * | 2011-03-07 | 2012-09-19 | 江苏凯吉生物科技有限公司 | Stable liposome and preparation method thereof |
| CN103610642A (en) * | 2013-12-10 | 2014-03-05 | 中国计量学院 | Lipidosome encapsulating epigallocatechin gallate and preparation method thereof |
-
2015
- 2015-12-15 CN CN201510934821.7A patent/CN105456193A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612124A (en) * | 2009-07-15 | 2009-12-30 | 吉林大学 | The preparation method of a kind of lipoid plastid and preparation thereof |
| CN102670508A (en) * | 2011-03-07 | 2012-09-19 | 江苏凯吉生物科技有限公司 | Stable liposome and preparation method thereof |
| CN103610642A (en) * | 2013-12-10 | 2014-03-05 | 中国计量学院 | Lipidosome encapsulating epigallocatechin gallate and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陆彬主编: "《中药新剂型与新技术》", 31 January 2008 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919824A (en) * | 2016-07-07 | 2016-09-07 | 北京浩奇科技有限责任公司 | EGCG-containing oily cosmetic, as well as preparation method and application thereof |
| CN107320716A (en) * | 2017-06-27 | 2017-11-07 | 珠海亿胜生物制药有限公司 | Basic fibroblast growth factor vesica and preparation method thereof |
| CN107320716B (en) * | 2017-06-27 | 2019-03-05 | 珠海亿胜生物制药有限公司 | Basic fibroblast growth factor vesica and preparation method thereof |
| CN109464298A (en) * | 2018-11-20 | 2019-03-15 | 江南大学 | A kind of preparation method and EGCG lipoid plastid gel of EGCG lipoid plastid gel |
| CN110999988A (en) * | 2019-12-20 | 2020-04-14 | 茗汲(浙江)生物科技有限公司 | Preparation method of white tea and tea seed oil microcapsules |
| CN116602959A (en) * | 2023-05-24 | 2023-08-18 | 广州中妆美业化妆品有限公司 | Composition liposome containing tea active ingredient and having anti-inflammatory and analgesic effects and application thereof |
| CN116602959B (en) * | 2023-05-24 | 2024-05-17 | 广州中妆美业化妆品有限公司 | Composition liposome containing tea active ingredient and having anti-inflammatory and analgesic effects and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khorasani et al. | Nanoliposome technology for the food and nutraceutical industries | |
| CN105456193A (en) | EGCC liposome preparation and preparation method thereof | |
| Alehosseini et al. | Electrospun curcumin-loaded protein nanofiber mats as active/bioactive coatings for food packaging applications | |
| Emami et al. | Liposomes as carrier vehicles for functional compounds in food sector | |
| Ataei et al. | Essential oils-loaded electrospun biopolymers: A future perspective for active food packaging | |
| Pando et al. | Preparation and characterization of niosomes containing resveratrol | |
| Tan et al. | Biopolymer-coated liposomes by electrostatic adsorption of chitosan (chitosomes) as novel delivery systems for carotenoids | |
| Puligundla et al. | Nanotechnological approaches to enhance the bioavailability and therapeutic efficacy of green tea polyphenols | |
| Feng et al. | Co‐encapsulation of resveratrol and epigallocatechin gallate in low methoxyl pectin‐coated liposomes with great stability in orange juice | |
| Silva-Weiss et al. | Design of dipalmitoyl lecithin liposomes loaded with quercetin and rutin and their release kinetics from carboxymethyl cellulose edible films | |
| Berendsen et al. | Spray dried double emulsions containing procyanidin-rich extracts produced by premix membrane emulsification: Effect of interfacial composition | |
| Xia et al. | Ferrous sulfate liposomes: preparation, stability and application in fluid milk | |
| Zou et al. | Characterization and bioavailability of tea polyphenol nanoliposome prepared by combining an ethanol injection method with dynamic high-pressure microfluidization | |
| CN104546538B (en) | A kind of VC-VE liposomes of Chitosan-coated and its preparation method and application | |
| Tan et al. | Polyelectrolyte microcapsules built on CaCO3 scaffolds for the integration, encapsulation, and controlled release of copigmented anthocyanins | |
| Otake et al. | One-step preparation of chitosan-coated cationic liposomes by an improved supercritical reverse-phase evaporation method | |
| Chen et al. | Construction of dual-compartmental micro-droplet via shrimp ferritin nanocages stabilized Pickering emulsions for co-encapsulation of hydrophobic/hydrophilic bioactive compounds | |
| CN105639654A (en) | Preparation method of red bayberry anthocyanin nano liposomes | |
| Tan et al. | Yeast cell-derived delivery systems for bioactives | |
| Cheng et al. | The stabilization and antioxidant performances of coenzyme Q10-loaded niosomes coated by PEG and chitosan | |
| JP5494054B2 (en) | Method for producing liposomes by two-stage emulsification | |
| Tomou et al. | Recent advances in nanoformulations for quercetin delivery | |
| Mejías et al. | Provitamin supramolecular polymer micelle with pH responsiveness to control release, bioavailability enhancement and potentiation of cytotoxic efficacy | |
| Chen et al. | Fabrication, characterization, and in vitro digestion of bamboo leaf extract loaded liposomes | |
| CN103725017A (en) | Fish collagen antibacterial film with slow release effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160406 |
|
| WD01 | Invention patent application deemed withdrawn after publication |